Autologous bone marrow stem cell transplantation in critical limb ischemia: A meta-analysis of randomized controlled trials

Chinese Medical Journal

Volumn 125, Issue 23, 2012, Pages 4296-4300

  Liu, Fu Peng ^a   Dong, Jian Jun ^b   Sun, Shu Juan ^a   Gao, Wei Yi ^a   Zhang, Zhong Wen ^a   Zhou, Xiao Jun ^a   Yang, Liu ^a   Zhao, Jun Yu ^a   Yao, Jin Ming ^a   Liu, Meng ^a   Liao, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Bone marrow derived cells; Critical limb ischemia; Meta analysis; Stem cells; Transplantation

Indexed keywords

AMPUTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CRITICAL LIMB ISCHEMIA; DATA EXTRACTION; FOLLOW UP; HEMATOCRIT; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT OUTCOME; ULCER HEALING;

BONE MARROW TRANSPLANTATION; HUMANS; ISCHEMIA; LOWER EXTREMITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84870743299     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.23.024     Document Type: Article

References (18)

1. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-538.
2. Nehler MR, McDermott MM, Treat-Jacobson D, Chetter I, Regensteiner JG. Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med 2003; 8: 115-126.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 33 Suppl 1: S1-S75.
4. Stem cell therapy in PAD. Eur J Vasc Endovasc Surg 2010; 39 Suppl 1: S38-S43.
5. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209: 10-17.
6. Powell RJ, Comerota AJ, Berceli SA, Guzman R, Henry TD, Tzeng E, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg 2011; 54: 1032-1041.
7. Iafrati MD, Hallett JW, Geils G, Pearl G, Lumsden A, Peden E, et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg 2011; 54: 1650-1658.
8. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 2012; 20: 1280-1286.
9. Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schluter M, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4: 26-37.
10. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92: 26-36.
11. Benoit E, O'Donnell TF, Jr., Iafrati MD, Asher E, Bandyk DF, Hallett JW, et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011; 9: 165.
12. Procházka V, Gumulec J, Jaluvka F, Salounova D, Jonszta T, Czerny D, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010; 19: 1413-1424.
13. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-2160.
14. Barc P, Skora J, Pupka A, Turkiewicz D, Dorobisz AT, Garcarek J, et al. Bone-marrow cells in therapy of critical limb ischaemia of lower extremities - Own experience. Acta Angiologica 2006; 12: 155-166.
15. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 29: 1807-1818.
16. Klepanec A, Mistrik M, Altaner C, Valachovicova M, Olejarova I, Slysko R, et al. No difference in intraarterial and intramuscular delivery of autologous bone-marrow cells in patients with advanced critical limb ischemia. Cell Transplant 2012; Epub ahead of print.
17. Perin EC, Silva G, Gahremanpour A, Canales J, Zheng Y, Cabreira-Hansen MG, et al. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011; 78: 1060-1067.
18. Hernandez P, Cortina L, Artaza H, Pol N, Lam RM, Dorticos E, et al. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis 2007; 194: e52-e56.